NASDAQ:HALO

Halozyme Therapeutics Stock News

etoro logo Buy HALO
*Your capital is at risk
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Great West Life Assurance Co. Can purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to the company in its most recent 13F filing with th
Amalgamated Bank grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fir
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Algert Global LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 42.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 89,363 shares of the biopharmac
Blair William & Co. IL acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. T
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Kenneth J. Kelley acquired 52,629 shares of Halozyme Therapeutics stock in a transaction on Thursday, March 19th. The shares were bought at an averag
Those following along with Halozyme Therapeutics, Inc. (NASDAQ:HALO) will no doubt be intrigued by the recent purchase...

A Director at Halozyme (HALO) is Buying Shares

02:45am, Friday, 20'th Mar 2020
Yesterday, a Director at Halozyme (HALO), Kenneth Kelley, bought shares of HALO for $748.2K. This recent transaction increases Kenneth Kelley's holding in
Yesterday, a Director at Halozyme ( HALO – Research Report ), Kenneth Kelley , bought shares of HALO for $748.2K. This recent transaction increases Kenneth Kelley’s holding in the company by 27.72
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE